We are dedicated to becoming the global leader in personalized treatment of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations.
We strive to make a difference in the lives of people affected by neurodegenerative diseases such as Alzheimer’s disease. Partnerships and collaborations are a key element of our business strategy in order to maximize the value of our innovative therapeutic and diagnostic products.
We have signed a number of licensing and collaboration agreements with leading companies to accelerate the development of our product pipeline.
In April 2016 AC Immune signed a research and development collaboration agreement with Biogen to develop PET-ligands for two protein targets involved in pathogenesis of neurodegenerative diseases - alpha-synuclein and TDP43. The collaboration lasts for an initial three years AC Immune will lead the chemistry and biology research for both the alpha-synuclein-PET tracer and the TDP-43-PET tracer program. Biogen will lead the scientific assessment and the radiopharmaceutical development of the AC Immune compounds. The two companies will share the clinical program design.
In 2006 AC Immune closed an exclusive out-licensing agreement for its anti-Abeta antibody program with Genentech, under which Genentech develops crenezumab for the treatment of Alzheimer's disease. AC Immune received an upfront payment and milestone payments upon the start of phase 1, phase 2 and phase 3 respectively. The contract provides potential total revenues of over USD 300 million for AC Immune through payments upon successful completion of clinical and regulatory milestones in Alzheimer's disease and additional applications. Additionally, the company is entitled to receive royalties on net sales of products resulting from this partnership.
In June 2012 AC Immune has entered into a second exclusive worldwide license agreement and research collaboration with Genentech for the research, development and commercialization of AC Immune’s anti-Tau antibodies for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases. AC Immune received an upfront payment and is eligible to receive research, development and commercialization milestone payments totaling more than Swiss Francs 400 million for Alzheimer's disease and other indications. Milestone payments were received for the selection of a lead candidate and for the commencement of a phase 1 clinical trial. Additionally, the company is entitled to receive royalties on net sales of products resulting from this partnership.
Beginning of 2015 AC Immune entered into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals, Inc., to develop and commercialize therapeutic anti-Tau vaccines for the treatment of Alzheimer’s disease and potentially other tauopathies. AC Immune received an upfront payment and is eligible to receive research, development and commercialization milestone payments potentially totaling up to CHF 500 million for Alzheimer's disease and a potential second indication. Additionally, the company is entitled to receive royalties on net sales of products resulting from this partnership.
Nestlé Institute of Health Sciences
In September 2015 AC Immune signed a research collaboration agreement with the Nestlé Institute of Health Sciences SA (NIHS), a fundamental research institute of the global nutrition, health and wellness company Nestlé, to develop a novel, minimally invasive Tau diagnostic assay for the early diagnosis of Alzheimer’s disease. AC Immune will provide its world leading expertise in the biology and pathology of Tau as well as committing its laboratory capabilities to support the collaborative research program. NIHS will apply its proprietary multiplexed antibody technology platform to the research program with the goal of identifying and validating a highly sensitive diagnostic assay for the detection of Tau in human cerebrospinal fluid (CSF) and blood plasma.
The exclusive worldwide out-licensing agreement for AC Immune's Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of Alzheimer’s disease (AD) and potential Tau-related disorders with Piramal was closed in May 2014. AC Immune received an upfront payment and is eligible for significant milestone payments on products achieving development goals in AD and other Tauopathies. Additionally, AC Immune is entitled to receive royalties on net sales of products resulting from the partnership.
In May 2017 AC Immune and Essex Bio-Technology Limited entered into a research collaboration agreement to undertake the pre-clinical and clinical co-development of a novel biological therapeutic for the treatment of neurodegenerative diseases and neuroinflammation. The objective of the collaboration is the development of a recombinant protein therapeutic candidate acting on a unique neuroprotective mechanism for treatment of neurological diseases, such as Alzheimer’s disease and frontotemporal dementia. Essex will provide joint research commitment as well as financial support to AC Immune for the pre-IND development of the biological agent. The two companies will pursue a joint clinical development and commercial strategy for a potential product.
We welcome the opportunity to learn more about how we can work together. To discuss partnering opportunities with AC Immune, please contact:
Dr. Richard Munton
Head of Business Development
Phone : +41-21 345 91 21
Fax : +41-21 345 91 20